<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04421222</url>
  </required_header>
  <id_info>
    <org_study_id>EPI-7386-CS-001</org_study_id>
    <nct_id>NCT04421222</nct_id>
  </id_info>
  <brief_title>Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer</brief_title>
  <acronym>EPI-7386</acronym>
  <official_title>A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ESSA Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ESSA Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, clinical research study of EPI-7386, an investigational drug being studied&#xD;
      as a treatment for patients with prostate cancer. All patients in the study will receive&#xD;
      EPI-7386.&#xD;
&#xD;
      Since this is the first study of EPI-7386 in humans, there is no information about how it&#xD;
      affects people or what dose should be used. Therefore, the main purpose of this study is to&#xD;
      assess the safety (side effects) of EPI-7386 and to find a dose that can be given without&#xD;
      unacceptable side effects.&#xD;
&#xD;
      There are other important things that will be evaluated during the study:&#xD;
&#xD;
        -  How the amount of EPI-7386 in the blood changes over time.&#xD;
&#xD;
        -  The effect of EPI-7386 on prostate cancer.&#xD;
&#xD;
        -  The effect of EPI-7386 on certain substances in the body.&#xD;
&#xD;
        -  The possibility that EPI-7386 can interact with other drugs.&#xD;
&#xD;
      The study will be conducted in 2 parts:&#xD;
&#xD;
        -  Part A: To evaluate the safety and tolerability of EPI-7386 as a single agent via 2&#xD;
           Phases:&#xD;
&#xD;
             -  Phase 1a: Dose Escalation (mCRPC)&#xD;
&#xD;
             -  Phase 1b: Dose Expansion (mCRPC)&#xD;
&#xD;
        -  Part B: To evaluate 2 parallel enrolling cohorts (Cohort 1 and Cohort 2) of EPI-7386 in&#xD;
           combination of apalutamide acetate + prednisone (AAP) or apalutamide (APA):&#xD;
&#xD;
             -  Cohort 1: Combination with AAP in mHSPC or mCRPC patients&#xD;
&#xD;
             -  Cohort 2: Will evaluate the anti-tumor activity of EPI-7386 for a limited window of&#xD;
                time (12 weeks EPI-7386 monotherapy prior to the start of combination therapy with&#xD;
                APA) in nmCRPC patients unperturbed by previous 2nd generation anti-androgen&#xD;
                therapies or chemotheraphy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary safety variable for Part A/Phase 1a of the study is the incidence of protocol-defined DLT during the DLT assessment period (first 28 days of dosing).</measure>
    <time_frame>2 months</time_frame>
    <description>The DLTs will be characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for AEs [NCI CTCAE version 5.0]), timing, seriousness, and relationship to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary efficacy variable for Part A/Phase 1b is the proportion of patients with a decline from baseline in PSA blood concentrations of ≥50% and ≥90% at any time point during daily dosing with EPI-7386.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary efficacy variable for Part B/Cohort 1 is the incidence of protocol-defined DLT during the DLT assessment period (first 28 days of dosing); TEAEs; abnormalities in clinical laboratory parameters/vitals/ECGs; and changes in ECOG.</measure>
    <time_frame>6 months</time_frame>
    <description>The DLTs will be characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for AEs [NCI CTCAE version 5.0]), timing, seriousness, and relationship to study drug.&#xD;
TEAEs and abnormalities in clinical laboratory parameters/vitals/ECGs will be characterized by type, frequency, severity, timing, seriousness and relationship to study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary efficacy variable for Part B/Cohort 2 is the proportion of patients with a decline from baseline in PSA blood concentrations of ≥50% and ≥90% at any time point during daily dosing with single agent EPI-7386 up to Week 12.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Part A/Phase 1a: Cohort 1 (Completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A/Phase 1a: Cohort 2 (Completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A/Phase 1a: Cohort 3 (Completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A/Phase 1a: Cohort 4 (Completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A/Phase 1a: Cohort 5 (Completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A/Phase 1a: Cohort 6 (Completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A/Phase 1a: Cohort 7 (Completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A/Phase 1b: Cohort 1 (Completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg EPI-7386 BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A/Phase 1b: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg EPI-7386 QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B/Cohort 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B/Cohort 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B/Cohort 1c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B/Cohort 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg EPI-7386 monotherapy for 12 weeks then 600 mg EPI-7386 + 240 mg Apalutamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B/Cohort 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg EPI-7386 monotherapy for 12 weeks then 800 mg EPI-7386 + 240 mg Apalutamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B/Cohort 2c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg EPI-7386 monotherapy for 12 weeks then 1200 mg EPI-7386 + 240 mg Apalutamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-7386 (QD)</intervention_name>
    <description>Once daily oral dose of EPI-7386</description>
    <arm_group_label>Part A/Phase 1a: Cohort 1 (Completed)</arm_group_label>
    <arm_group_label>Part A/Phase 1a: Cohort 2 (Completed)</arm_group_label>
    <arm_group_label>Part A/Phase 1a: Cohort 3 (Completed)</arm_group_label>
    <arm_group_label>Part A/Phase 1a: Cohort 4 (Completed)</arm_group_label>
    <arm_group_label>Part A/Phase 1a: Cohort 5 (Completed)</arm_group_label>
    <arm_group_label>Part A/Phase 1b: Cohort 2</arm_group_label>
    <arm_group_label>Part B/Cohort 1a</arm_group_label>
    <arm_group_label>Part B/Cohort 1b</arm_group_label>
    <arm_group_label>Part B/Cohort 2a</arm_group_label>
    <arm_group_label>Part B/Cohort 2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-7386 (BID)</intervention_name>
    <description>Twice daily oral dose of EPI-7386</description>
    <arm_group_label>Part A/Phase 1a: Cohort 6 (Completed)</arm_group_label>
    <arm_group_label>Part A/Phase 1a: Cohort 7 (Completed)</arm_group_label>
    <arm_group_label>Part A/Phase 1b: Cohort 1 (Completed)</arm_group_label>
    <arm_group_label>Part B/Cohort 1c</arm_group_label>
    <arm_group_label>Part B/Cohort 2c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate</intervention_name>
    <description>Once daily dose of abiraterone acetate</description>
    <arm_group_label>Part B/Cohort 1a</arm_group_label>
    <arm_group_label>Part B/Cohort 1b</arm_group_label>
    <arm_group_label>Part B/Cohort 1c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Once daily dose of apalutamide</description>
    <arm_group_label>Part B/Cohort 2a</arm_group_label>
    <arm_group_label>Part B/Cohort 2b</arm_group_label>
    <arm_group_label>Part B/Cohort 2c</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part A/Phase 1a (Dose Escalation) Inclusion Criteria:&#xD;
&#xD;
          -  Male 18 years of age or older.&#xD;
&#xD;
          -  Histologically, pathologically, or cytologically confirmed prostate cancer without&#xD;
             small cell features.&#xD;
&#xD;
          -  Evidence of castration-resistant prostate cancer (CRPC).&#xD;
&#xD;
          -  Presence of metastatic disease at study entry documented by 1 or more bone lesions on&#xD;
             bone scan or by soft tissue disease observed by CT/MRI.&#xD;
&#xD;
          -  Limited further treatment options available known to confer clinical benefit in this&#xD;
             disease setting from the perspective of the treating physician. Specifically, patients&#xD;
             must have progressed on at least 2, but not more than 3, prior approved systemic&#xD;
             therapies for mCRPC which include at least one, but not more than 2, second generation&#xD;
             anti-androgen drug.&#xD;
&#xD;
          -  Patients may have received prior docetaxel for mCSPC or mCRPC but must not have had&#xD;
             disease progression during, or within 6 months of completing chemotherapy. Only one&#xD;
             line of prior chemotherapy is allowed.&#xD;
&#xD;
          -  Evidence of progressive disease defined as 1 or more Prostate Cancer Working Group 3&#xD;
             (PCWG3) criteria.&#xD;
&#xD;
          -  The patient must have recovered from toxicities related to any prior treatments.&#xD;
&#xD;
          -  Castrate at screening.&#xD;
&#xD;
          -  Patients receiving bisphosphonates or other approved bone-targeting therapy must be on&#xD;
             a stable dose for at least 4 weeks prior to the start of study drug.&#xD;
&#xD;
          -  Demonstrate adequate organ function.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.&#xD;
&#xD;
        Part A/Phase 1b (Dose Expansion) Inclusion Criteria:&#xD;
&#xD;
        The inclusion criteria for this cohort are the same as for Phase 1a with the exception of:&#xD;
        limit of prior therapies to 2 and prior chemotherapy is not allowed for this cohort of&#xD;
        patients.&#xD;
&#xD;
        Part B/Cohort 1 (EPI-7386 in combination with AAP) Inclusion Criteria:&#xD;
&#xD;
          -  Patients are eligible to enroll in this cohort if they meet the clinical criteria for&#xD;
             receiving AAP as standard of care treatment as per label (i.e., high-risk mHSPC or&#xD;
             mCRPC).&#xD;
&#xD;
          -  All other inclusion criteria listed for Part A/Phase 1a apply except for those that do&#xD;
             not apply to mHSPC or mCRPC patients (i.e. evidence of CRPC and limited treatment&#xD;
             options for mCRPC).&#xD;
&#xD;
        Part B/Cohort 2 (Window of Opportunity with clinical endpoints followed by combination with&#xD;
        Apalutamide)&#xD;
&#xD;
          -  Male 18 years of age or older.&#xD;
&#xD;
          -  Histologically, pathologically, or cytologically confirmed prostate cancer without&#xD;
             small cell features.&#xD;
&#xD;
          -  Evidence of castration-resistant prostate cancer (CRPC).&#xD;
&#xD;
          -  Patients who received a first generation anti-androgen as part of an initial combined&#xD;
             androgen blockade therapy or as second-line hormonal therapy must show continuing&#xD;
             disease (PSA) progression off the anti-androgen for at least 4 weeks prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  At least 4 weeks must have elapsed from the use of 5-α reductase inhibitors,&#xD;
             estrogens, and any other anti-cancer therapy prior to enrollment.&#xD;
&#xD;
          -  At least 4 weeks must have elapsed from major surgery or radiation therapy prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  The patient must have recovered from toxicities related to any prior treatments.&#xD;
&#xD;
          -  Castrate at screening.&#xD;
&#xD;
          -  Demonstrate adequate organ function.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.&#xD;
&#xD;
        Part A Phase 1a and Phase 1b Exclusion Criteria:&#xD;
&#xD;
          -  Biologic anti-cancer therapy or a cytotoxic chemotherapy within 4 weeks prior to the&#xD;
             start of study drug.&#xD;
&#xD;
          -  Use of hormonal agents with anti-tumor activity against prostate cancer within 4 weeks&#xD;
             prior to the start of study drug.&#xD;
&#xD;
          -  Any lutamides or abiraterone within 14 days or 5 half-lives, whichever is longer prior&#xD;
             to start of study drug.&#xD;
&#xD;
          -  Use of radium-223 dichloride or other radioligand/radiopharmaceutical within 28 days&#xD;
             prior to the start of study drug.&#xD;
&#xD;
          -  Received limited-field palliative bone radiotherapy &gt;5 fractions and/or any&#xD;
             radiotherapy within 2 weeks prior to the start of study drug.&#xD;
&#xD;
          -  Received a blood transfusion within 28 days of screening.&#xD;
&#xD;
          -  Received prior chemotherapy (for Part 1b Cohort A only).&#xD;
&#xD;
          -  Known intra-cerebral disease or brain metastasis unless adequately treated and stable&#xD;
             for the last 4 weeks before enrollment.&#xD;
&#xD;
          -  Spinal cord compression.&#xD;
&#xD;
          -  Diagnosis of another invasive malignancy within the previous 3 years other than&#xD;
             curatively treated non-melanomatous skin cancer or superficial urothelial carcinoma.&#xD;
&#xD;
          -  Gastrointestinal disorder affecting absorption.&#xD;
&#xD;
          -  Significant cardiovascular disease.&#xD;
&#xD;
          -  Concurrent disease or any clinically significant abnormality.&#xD;
&#xD;
          -  Use of strong inducers of CYP3A within 14 days of the first dose of study drug.&#xD;
&#xD;
        Part A Phase 1b (Dose Expansion) Exclusion Criteria:&#xD;
&#xD;
        The exclusion criteria for this cohort are the same as the criteria from Phase 1a with the&#xD;
        addition of the following:&#xD;
&#xD;
        • Any prior treatment with chemotherapy.&#xD;
&#xD;
        Part B Cohort 1 (EPI-7386 in combination with AAP) Exclusion Criteria:&#xD;
&#xD;
        The exclusion criteria for this cohort are the same as the criteria from Phase 1a with the&#xD;
        addition of the following:&#xD;
&#xD;
          -  Use of concomitant CYP2D6 substrates with narrow therapeutic index.&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to the excipients of AA (refer to AA&#xD;
             Investigator's Brochure [IB] or package inserts as appropriate).&#xD;
&#xD;
        Part B Cohort 2 (Window of Opportunity with clinical endpoints followed by combination with&#xD;
        Apalutamide)&#xD;
&#xD;
          -  Presence of distant metastases, including visceral, nodal and bones involvement.&#xD;
             Exception: pelvic lymph nodes &lt; 2 cm in short axis (N1) located below the iliac&#xD;
             bifurcation are allowed.&#xD;
&#xD;
          -  Symptomatic loco-regional disease requiring medical intervention, such as moderate or&#xD;
             severe urinary obstruction or hydronephrosis due to primary tumor.&#xD;
&#xD;
          -  Prior treatment with second generation anti-androgens.&#xD;
&#xD;
          -  Prior treatment with CYP17 inhibitors.&#xD;
&#xD;
          -  Prior treatment with radiopharmaceutical agents, immunotherapy, or any other&#xD;
             investigational agent for nmCRPC.&#xD;
&#xD;
          -  Prior chemotherapy.&#xD;
&#xD;
          -  History or evidence of: prior malignancy (other than adequately treated basal cell or&#xD;
             squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ&#xD;
             currently in complete remission) within 3 years prior to enrollment; severe/unstable&#xD;
             angina, myocardial infarction, symptomatic congestive heart failure, arterial or&#xD;
             venous thromboembolic events; uncontrolled hypertension.&#xD;
&#xD;
          -  Gastrointestinal disorder affecting absorption.&#xD;
&#xD;
          -  Use of strong inducers of CYP3A within 14 days of the first dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen Villaluna</last_name>
    <phone>650-449-8400</phone>
    <email>kvillaluna@essapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology Oncology Associates of the Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of NV Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Great Lakes Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BC Cancer</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2023</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>September 13, 2023</last_update_submitted>
  <last_update_submitted_qc>September 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04421222
org study id: EPI-7386-CS-001
nct id: NCT04421222
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This is a phase I, clinical research study of EPI-7386, an investigational drug being studied
      as a treatment for patients with prostate cancer. All patients in the study will receive
      EPI-7386.

      Since this is the first study of EPI-7386 in humans, there is no information about how it
      affects people or what dose should be used. Therefore, the main purpose of this study is to
      assess the safety (side effects) of EPI-7386 and to find a dose that can be given without
      unacceptable side effects.

      There are other important things that will be evaluated during the study:

        -  How the amount of EPI-7386 in the blood changes over time.

        -  The effect of EPI-7386 on prostate cancer.

        -  The effect of EPI-7386 on certain substances in the body.

        -  The possibility that EPI-7386 can interact with other drugs.

      The study will be conducted in 2 parts:

        -  Part A: To evaluate the safety and tolerability of EPI-7386 as a single agent via 2
           Phases:

             -  Phase 1a: Dose Escalation (mCRPC)

             -  Phase 1b: Dose Expansion (mCRPC)

        -  Part B: To evaluate 2 parallel enrolling cohorts (Cohort 1 and Cohort 2) of EPI-7386 in
           combination of apalutamide acetate + prednisone (AAP) or apalutamide (APA):

             -  Cohort 1: Combination with AAP in mHSPC or mCRPC patients

             -  Cohort 2: Will evaluate the anti-tumor activity of EPI-7386 for a limited window of
                time (12 weeks EPI-7386 monotherapy prior to the start of combination therapy with
                APA) in nmCRPC patients unperturbed by previous 2nd generation anti-androgen
                therapies or chemotheraphy.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: The primary safety variable for Part A/Phase 1a of the study is the incidence of protocol-defined DLT during the DLT assessment period (first 28 days of dosing).
time frame: 2 months
description: The DLTs will be characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for AEs [NCI CTCAE version 5.0]), timing, seriousness, and relationship to study drug.
measure: The primary efficacy variable for Part A/Phase 1b is the proportion of patients with a decline from baseline in PSA blood concentrations of ≥50% and ≥90% at any time point during daily dosing with EPI-7386.
time frame: 12 months
measure: The primary efficacy variable for Part B/Cohort 1 is the incidence of protocol-defined DLT during the DLT assessment period (first 28 days of dosing); TEAEs; abnormalities in clinical laboratory parameters/vitals/ECGs; and changes in ECOG.
time frame: 6 months
description: The DLTs will be characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for AEs [NCI CTCAE version 5.0]), timing, seriousness, and relationship to study drug.
TEAEs and abnormalities in clinical laboratory parameters/vitals/ECGs will be characterized by type, frequency, severity, timing, seriousness and relationship to study treatment.
measure: The primary efficacy variable for Part B/Cohort 2 is the proportion of patients with a decline from baseline in PSA blood concentrations of ≥50% and ≥90% at any time point during daily dosing with single agent EPI-7386 up to Week 12.
time frame: 4 months
arm group label: Part A/Phase 1a: Cohort 1 (Completed)
arm group type: Experimental
description: 200 mg EPI-7386
arm group label: Part A/Phase 1a: Cohort 2 (Completed)
arm group type: Experimental
description: 400 mg EPI-7386
arm group label: Part A/Phase 1a: Cohort 3 (Completed)
arm group type: Experimental
description: 600 mg EPI-7386
arm group label: Part A/Phase 1a: Cohort 4 (Completed)
arm group type: Experimental
description: 800 mg EPI-7386
arm group label: Part A/Phase 1a: Cohort 5 (Completed)
arm group type: Experimental
description: 1000 mg EPI-7386
arm group label: Part A/Phase 1a: Cohort 6 (Completed)
arm group type: Experimental
description: 800 mg EPI-7386
arm group label: Part A/Phase 1a: Cohort 7 (Completed)
arm group type: Experimental
description: 1200 mg EPI-7386
arm group label: Part A/Phase 1b: Cohort 1 (Completed)
arm group type: Experimental
description: 600 mg EPI-7386 BID
arm group label: Part A/Phase 1b: Cohort 2
arm group type: Experimental
description: 600 mg EPI-7386 QD
arm group label: Part B/Cohort 1a
arm group type: Experimental
description: 600 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone
arm group label: Part B/Cohort 1b
arm group type: Experimental
description: 800 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone
arm group label: Part B/Cohort 1c
arm group type: Experimental
description: 1200 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone
arm group label: Part B/Cohort 2a
arm group type: Experimental
description: 600 mg EPI-7386 monotherapy for 12 weeks then 600 mg EPI-7386 + 240 mg Apalutamide
arm group label: Part B/Cohort 2b
arm group type: Experimental
description: 800 mg EPI-7386 monotherapy for 12 weeks then 800 mg EPI-7386 + 240 mg Apalutamide
arm group label: Part B/Cohort 2c
arm group type: Experimental
description: 1200 mg EPI-7386 monotherapy for 12 weeks then 1200 mg EPI-7386 + 240 mg Apalutamide
intervention type: Drug
intervention name: EPI-7386 (QD)
description: Once daily oral dose of EPI-7386
arm group label: Part A/Phase 1a: Cohort 1 (Completed)
arm group label: Part A/Phase 1a: Cohort 2 (Completed)
arm group label: Part A/Phase 1a: Cohort 3 (Completed)
arm group label: Part A/Phase 1a: Cohort 4 (Completed)
arm group label: Part A/Phase 1a: Cohort 5 (Completed)
arm group label: Part A/Phase 1b: Cohort 2
arm group label: Part B/Cohort 1a
arm group label: Part B/Cohort 1b
arm group label: Part B/Cohort 2a
arm group label: Part B/Cohort 2b
intervention type: Drug
intervention name: EPI-7386 (BID)
description: Twice daily oral dose of EPI-7386
arm group label: Part A/Phase 1a: Cohort 6 (Completed)
arm group label: Part A/Phase 1a: Cohort 7 (Completed)
arm group label: Part A/Phase 1b: Cohort 1 (Completed)
arm group label: Part B/Cohort 1c
arm group label: Part B/Cohort 2c
intervention type: Drug
intervention name: Abiraterone acetate
description: Once daily dose of abiraterone acetate
arm group label: Part B/Cohort 1a
arm group label: Part B/Cohort 1b
arm group label: Part B/Cohort 1c
intervention type: Drug
intervention name: Apalutamide
description: Once daily dose of apalutamide
arm group label: Part B/Cohort 2a
arm group label: Part B/Cohort 2b
arm group label: Part B/Cohort 2c
criteria: 
gender: Male
gender based: Yes
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Karen Villaluna
phone: 650-449-8400
email: kvillaluna@essapharma.com
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Completed
facility: 
status: Not yet recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
facility: 
status: Recruiting
country: Canada
country: United States
responsible party type: Sponsor
mesh term: Prostatic Neoplasms
mesh term: Abiraterone Acetate